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Background: Androgens drive the onset and progression of prostate cancer (PCa) via androgen receptor (AR)
signalling. The principal treatment for PCa is androgen deprivation therapy, although the majority of patients
eventually develop a lethal castrate-resistant form of the disease, where despite low serum testosterone levels AR
signalling persists. Advanced PCa often has hyper-activated RAS/ERK1/2 signalling thought to be due to loss of
function of key negative regulators of the pathway, the details of which are not fully understood.
Methods: We recently carried out a genome-wide study and identified a subset of 226 novel androgen-regulated
genes (PLOS ONE 6:e29088, 2011). In this study we have meta-analysed this dataset with genes and pathways
frequently mutated in PCa to identify androgen-responsive regulators of the RAS/ERK1/2 pathway.
Results: We find the PTGER4 and TSPYL2 genes are up-regulated by androgen stimulation and the ADCY1, OPKR1,
TRIB1, SPRY1 and PTPRR are down-regulated by androgens. Further characterisation of PTPRR protein in LNCaP cells
revealed it is an early and direct target of the androgen receptor which negatively regulates the RAS/ERK1/2
pathway and reduces cell proliferation in response to androgens.
Conclusion: Our data suggest that loss of PTPRR in clinical PCa is one factor that might contribute to activation of
the RAS/ERK1/2 pathway.
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Prostate cancer (PCa) is the most commonly-diagnosed
malignancy in men [1], and is driven by androgen hor-
mones acting via their cognate nuclear androgen receptor
(AR) transcription factor. The AR exerts its transcriptional
effects by binding to DNA sequences termed androgen
response elements (AREs) within promoter regions of a
number of androgen-regulated genes, including genes
encoding cell cycle regulators and regulators of central
metabolism and biosynthesis [2]. An important feature of
PCa is prognostic heterogeneity: while some prostate
cancers can remain indolent for many years others can
become much more rapidly aggressive. Distinguishing key* Correspondence: jennifer.munkley@ncl.ac.uk
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unless otherwise stated.signatures between these different cancer types is a key
goal. Androgen deprivation therapy (ADT) is the principal
treatment for advanced PCa, although, over time, the
disease becomes castration-resistant (CRPCa) with limited
treatment options [3]. Persistence of AR signalling and
reprogramming of the AR transcriptional landscape may
underlie progression to CRPCa [4,5], and highlights the
importance of AR biology in advanced PCa. Hence,
increasing our understanding of the AR signalling in PCa
cells should lead to more effective treatment strategies for
advanced PCa.
Recently, reciprocal cross-talk between the PI3K
pathway and AR signalling has been highlighted as a
potential mechanism underlying CRPCa [6]. Alterations
in PI3K signalling in advanced PCa are predominantly
driven by loss of the tumour suppressor gene PTEN
which contributes to the progression to invasive diseasel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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activation of the RAS/ERK1/2 pathway [10-12] thought to
be driven by loss of function of key negative regulators of
the pathway [13]. Although RAS/ERK1/2 activation alone
cannot initiate PCa development, it can serve as a
potentiating second hit to loss of PTEN to accelerate PCa
progression [13].
Because of its established importance in clinical prostate
cancer, the identification of new mechanisms through
which the RAS/RAF/MAPK/ERK pathway is regulated is
of great interest. We recently carried out genome-wide
exon-specific profiling of PCa cells to identify novel
androgen-regulated transcriptional events [14]. As well
as identifying a number of alternative mRNA isoforms
[15], we also identified a subset of 226 novel androgen-
regulated genes [14]. In the light of evidence implica-
ting cross-talk with AR, we searched this dataset for
novel androgen-regulated genes associated with RAS/
ERK1/2 signalling.
Methods
IPA Pathway analysis
Gene lists from Rajan et al. [14] were uploaded to the
web-based Ingenuity Pathway Analysis (IPA; Ingenuity
Systems) software programme, and the “Core Analysis”
function was used to study direct and indirect regulatory
relationships between genes and their known biological
functions.
Antibodies
The following antibodies were used in the study: anti-
PTPRR rabbit polyclonal (17937 Proteintech), anti-
phospho-p44/42 MAPK mouse monoclonal (Erk1/2
Thr202/Tyr204) (Cell signalling 9106), anti-ERK2 mouse
monoclonal (1647 Santa Cruz), anti-actin rabbit polyclonal
(A2668, Sigma), anti-AR mouse antibody (BD Bioscience,
554226), anti-FLAG mouse monoclonal (F3165, Sigma),
anti-PTEN rabbit polyclonal (Cell Signalling 138G6), anti-
α-Tubulin mouse monoclonal (Sigma T5168), normal
rabbit IgG (711-035-152 Jackson labs) and normal mouse
IgG (715-036-150 Jackson labs). The specificity of the
PTPRR antibody was confirmed by blocking with the
immunising peptide (ag12145 Proteintech) (Additional
file 1: Figure S2).
esiRNA
esiRNAs PTPRR and AR were obtained from Sigma-
Aldrich (EHU078991 and EHU025951).
DNA constructs
PTPRR cloned into pCDNA3.1 was a kind gift from
Mirco Menigatti, University of Zurich. The PTPRR open
reading frame was subsequently cloned into pCDNA5using NotI and XhoI for creation of the Flp-In™-293 stable
cell line.
Cell culture
Cell culture and androgen treatment of cells was as de-
scribed previously [14,15]. All cells were grown at 37°C
in 5% CO2. LNCaP cells (CRL-1740, ATCC) were main-
tained in RPMI-1640 with L-Glutamine (PAA Laborator-
ies, R15-802) supplemented with 10% Fetal Bovine
Serum (FBS) (PAA Laboratories, A15-101). For andro-
gen treatment of LNCaP cells, medium was supple-
mented with 10% dextran charcoal stripped FBS (PAA
Laboratories, A15-119) to produce a steroid-deplete me-
dium. Following culture for 72 hours, 10 nM synthetic
androgen analogue methyltrienolone (R1881) (Perkin–
Elmer, NLP005005MG) was added (Androgen +) or
absent (Steroid deplete) for the times indicated. Where
indicated, LNCaP cells were pre-treated for 1 hour with
vehicle (dimethylsulfoxide; DMSO) (Sigma, C1988) or
1 μg/ml cycloheximide (Sigma, D2438) prior to addition
of 10 nM R1881 for 24 hours as previously described
[16]. Similarly, LNCaP cells were pre-treated with with
10 μM bicalutamide (Casodex, AstraZeneca) or ethanol
(vehicle) for 2 hours prior to addition of 10 nM R1881
for 24 hours.
PC-3 (CRL-1435, ATCC), PC-3 M [17], CWR22Rv1
(CRL-2505, ATCC), DU145 (HTB-81, ATCC), and
BPH-1 cells [18] were maintained in RPMI-1640 with
L-Glutamine supplemented with 10% FBS. LNCaP-AI
and LNCaP-cdxR were derived from LNCaP parental
cells and maintained as previously described [19,20].
Stable LNCaP cell lines were generated by transfecting
cells using Lipofectamine 2000 (11668-027, Invitrogen),
followed by selection with 300 μg/ml Geneticin (Invitrogen,
10131019) (reduced to 150 μg/ml following the death of
untransfected cells) for at least four weeks. Flp-In™-293
cells (R750-07, Invitrogen) were maintained in DMEM
GlutaMax (Invitrogen, 10566-040), supplemented with
10% FBS (PAA Laboratories, A15-101) and stable cell lines
generated using the Flp-In T-Rex Core Kit (K6500-01,
Invitrogen) according to the manufacturer’s instructions.
Protein expression was induced using 1 μg/ml tetracycline
(T7660, Sigma) for 72 hours.
RT-qPCR
Cells were harvested and total RNA extracted using TRI-
zol (Invitrogen, 15596-026), according to manufacturer’s
instructions. RNA was treated with DNase 1 (Ambion)
and cDNA was generated by reverse transcription of
1 μg of total RNA using the Superscript VILO cDNA
synthesis kit (Invitrogen, 11754-050). Quantitative PCR
(qPCR) was performed in triplicate on cDNA using SYBR®
Green PCR Master Mix (Invitrogen, 4309155) using
Applied Biosystems 7900HT. Samples were normalised
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β –tubulin and actin. All primer sequences are listed in
Additional file 2: Table S2.
Proliferation assay
EdU incorporation was measured over 6 hours using the
Click-iT® EdU Alexa Fluor® 488 Imaging Kit (Invitrogen,
C10337) and counted using ImageJ. At least 3000 cells
were counted for each cell line across 3 coverslips. MTT
cell proliferation assay was carried out as per the manu-
facturer’s instructions (Cayman, 10009365) starting with
20,000 cells per well, with 9 replicates per sample.
Clinical samples
Six protein lysates from primary clinical prostate tumours
were used in this study. Full ethical approval was obtained
for human sample collection from the Northumberland,
Tyne and Wear NHS Strategic Health Authority Local
Research Ethics Committee (Ref: 2003/11) and written
informed consent for the use of surgically obtained
tissue was provided by all patients.
Results
Genes encoding components of RAS/ERK1/2 signalling
pathways are regulated by androgens in PCa cells
Complete gene lists from our ExonArray dataset [14]
were manually curated for androgen-regulated changes
within genes associated with RAS/ERK1/2 signalling.
We identified potent down-regulation of SPRY1 expres-
sion in response to androgens (Log2FC = -2.37 p < 0.001).
Full gene lists were then uploaded to the web-based
Ingenuity Pathway Analysis (IPA; Ingenuity Systems)
software programme, and the IPA ‘Core Analysis’ function
was used to identify novel androgen-regulated genes
within pathways associated with SPRY1 (Figure 1A &
Additional file 3: Table S1). This network analysis iden-
tified a number of novel androgen-regulated genes pre-
viously linked to the RAS/RAF/MAPK/ERK signalling
pathway. We confirmed androgen regulation of these
genes in LNCaP cells using real-time PCR (Figure 1B).
Two genes, PTGER4 and TSPYL2 were up-regulated in
response to androgens, whereas five others, ADCY1,
OPKR1, TRIB1, SPRY1 and PTPRR were repressed.
PTPRR is an early and direct target of the AR at the
mRNA and protein level
The above network analysis suggested that the PTPRR
gene is a novel androgen regulated target in the MAPK/
ERK signalling network. The genomic loci of AR binding
sites mapped by ChIP in LNCaP cells [4] were uploaded
onto the UCSC genome browser. Three known AR bind-
ing sites were identified in the vicinity of the PTPRR
gene, one of which was less than 5 kb upstream, and ano-
ther within an internal intronic region (Additional file 4:Figure S1). To test whether the PTPRR gene might be
under direct control of androgens through AR regulation,
we examined PTPRR expression in LNCaP cells grown in
steroid depleted medium and in cells treated with 10 nM
of the synthetic androgen analogue R1881 (methytrieno-
lone) by real-time qPCR over a 24 hour period (Figure 2A),
and at the protein level over 48 hours by western blotting
(Figure 2B). The specificity of the PTPRR antibody used
was confirmed by peptide blocking, detection of over-
expressed protein and detection of esiRNA mediated pro-
tein depletion (Figure 2B, Figure 3A and D and Additional
file 1: Figure S2). PTPRR expression was rapidly reduced
by 10 nM R1881 treatment at both the mRNA and protein
level. Repression of the PTPRR gene and protein was also
observed with a range of R1881 concentrations from
0.1 nM to 100 nM (Figure 2C). To test whether androgen-
mediated suppression of PTPRR expression was a direct
result of AR activity, we treated LNCaP cells with 10 nM
R1881 in the presence and absence of cycloheximide to
inhibit de novo protein synthesis. Androgen-mediated
down-regulation of PTPRR mRNA expression was still
observed in the presence of the protein synthesis in-
hibitor cycloheximide indicating that PTPRR repression
might be directly mediated by the AR (Figure 2D). Con-
firming this, we found androgen-mediated PTPRR
protein reduction was prevented by the AR antagonists
casodex (Figure 2E), and flutamide (Figure 2F), and
when cells are depleted of AR using esiRNA (Figure 2G).
Immunofluorescent staining of LNCaP cells grown in
the absence of androgens indicates that PTPRR protein
localises to the cytoplasm (Figure 2H). The structure of
the PTPRR gene and protein are illustrated in Figure 2I.
Re-expression of PTPRR in androgen treated LNCaP cells
reduces phosphorylation of ERK1/2 and regulates
downstream oncogenic transcription factors
The above data predicted that AR-regulated PTPRR
suppression in PCa cells may contribute to modulation
of RAS/ERK signaling in response to androgens. To test
this prediction, we created a stable LNCaP cell line in
which PTPRR was expressed under the control of the
CMV promoter and a control stable cell line transfected
with empty vector. This CMV promoter is active inde-
pendent of androgen stimulation. In the stable cell line
made with PTPRR , increased PTPRR gene expression
was detected at both the RNA level (by qRT-PCR rela-
tive to three housekeeping genes) and protein level (by
western analysis, relative to actin) compared to the con-
trol cell line made with empty vector (Figure 3A left and
middle panels).
Consistent with stable expression of PTPRR being suf-
ficient to dampen activity of the MAPK/ERK network,
LNCaP cells over-expressing PTPRR protein also showed
reduction in phosphorylated ERK1/2 in the presence of
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Figure 1 IPA Pathway Analysis of androgen regulated RAS/ERK1/2 signalling. Gene expression changes in LNCaP cells cultured in the
presence or absence of androgens for 24 hours. (A) Gene lists from Rajan et al. [14] were uploaded to the web-based Ingenuity Pathway Analysis
(IPA; Ingenuity Systems) software programme, and used to identify novel androgen-regulated genes associated with RAS/ERK1/2 signalling. Genes
up-regulated by androgens are highlighted in red, and down-regulated genes are in green. Further details are shown in Additional file 1: Table S1.
This highlighted the already well-characterised SPRY1 as an androgen-regulated negative regulator of ERK1/2, as well as some additional previously
uncharacterised targets, PTGER4, TSPYL2, ADCY1, OPKR1, TRIB1, PTGER4 and PTPRR. (B) Expression changes for 7 of these genes were validated by
real-time PCR.
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loading control, no change in total ERK1/2 levels was
detected (Figure 3A right panel). Correlating with this
modulation of the RAS/ERK pathway in response to
PTPRR expression, we also observed parallel repression
of three oncogenic transcription factors (c-fos, fra1 and
c-jun) known to be downstream regulated targets of
ERK1/2 [21] (Figure 3B).
Prostate cancer cells can be genetically heterogeneous,
and this can have important implications for prognosis
and treatment. We recently found a synergistic effect be-
tween loss of Pten and Spry2 in murine PCa progression
[22]. To test if the ability of PTPRR to negatively regulate
MAPK signalling might depend on cellular background
we generated a second stable cell line over-expressing
PTPRR in the HEK293 cell background which are not
derived from PCa cells but are PTEN positive (Figure 3C
top left panel). Consistent with an important role for cell
background in the response to PTPRR expression, over-
expression of PTPRR did not reduce either phosphoryl-
ation of ERK1/2 or the expression of c-fos, fra1 or c-jun in
the HEK293 cell background (Figure 3C). To test whether
endogenous levels of PTPRR alone were sufficient to
repress phosphorylation of ERK in the absence of other
signals in androgen-treated LNCaP cells, we depleted
PTPRR from androgen-depleted cells. Even though over-
expression of PTPRR in androgen treated LNCaP cells
was sufficient to repress ERK1/2 phosphorylation, de-
pletion of PTPRR alone by esiRNA in steroid depleted
LNCaP cells was insufficient to restore ERK1/2 phosphor-
ylation (Figure 3D). This result suggests that although
PTPRR has an important role in this pathway, additional
androgen-regulated proteins are involved in modulating
ERK1/2 phosphorylation in response to androgens. These
additional genes likely include other members of the RAS/
ERK1/2 pathway (identified by our IPA pathway analysis
in Figure 1).
Over-expression of PTPRR reduces LNCaP cell
proliferation
The down-regulation of c-fos, fra1 and and c-jun ex-
pression in stable LNCaP cells over-expressing PTPRR
suggested that androgen-mediated down-regulation of
PTPRR expression might be important for proliferationof LNCaP cells. To test for such an effect on cell prolif-
eration, we measured the proportion of cells in S-phase
in our stable LNCaP cell line expressing PTPRR, and
control LNCaP cells, using incorporation of EdU. Con-
sistent with a reduced rate of proliferation, LNCaP cells
over-expressing PTPRR in the presence of androgens
had a reduced amount of cells in S phase over a six
hour period (from 21.2% to 18.8%) relative to control
cells (p < 0.04) (Figure 3E). A decrease in LNCaP cell
growth in response to PTPRR expression was confirmed
using an MTT assay, where there was a significant
reduction in cell proliferation in PTPRR-expressing
cells (p < 0.003) (Figure 3F).
Low expression of PTPRR in Invasive PCa cell lines and
Clinical PCa tissue
We next examined PTPRR mRNA expression in a panel
of PCa cell lines of different invasive capabilities, and
with differing expression of PTEN (Figure 4A). Consist-
ent with AR-dependent down-regulation, there was re-
duced PTPRR expression in the casodex resistant LNCaP
derivative cell line relative to the androgen sensitive
LNCaP cells (p < 0.003) (Figure 4A). Consistent with po-
tential changes in PTPRR expression over disease progres-
sion, in these cell line models there was a low level of
expression of PTPRR in PC3 cells, but expression was
undetectable in their metastatic derivative PC3M.
The above data show that decreased PTPRR expres-
sion can be important to prostate cancer cell prolifera-
tion through modulation of the MAPK/ERK pathway,
and this might be modulated dependent on cellular
background including PTEN status. We examined PTPRR
gene expression in prostate cancer clinical samples using
previously published datasets that are publically available.
Comparison of PTPRR expression by Affymetrix Array of
14 samples reported a 3.381 fold reduction in prostate
cancer relative to normal tissue [23], and a 4.686 fold re-
duction in metastatic versus primary prostate cancer [24]
(Figure 4B). PTPRR expression was also significantly
reduced in 3 additional previously published datasets
[25-27] with 2 other datasets showing no significant
changes in PTPRR gene expression [11,28].
We tested PTPRR protein expression in a small panel of
clinical PCa samples. Although this was a small sample
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Figure 2 PTPRR expression is an early and directly repressed target of the AR. (A) LNCaP cells were cultured in medium supplemented
with 10% dextran charcoal stripped FBS to produce a steroid deplete medium. Following culture for 72 hours, cells were treated with 10 nM
synthetic androgen analogue methyltrienolone (R1881) for the times indicated. (A) Expression of PTPRR mRNA in cells grown in steroid deplete
(SD) or androgen (A+) treated conditions over a 24 hours period. The response to androgens was confirmed using PSA (KLK3) expression (not
shown). (B) Expression of PTPRR protein is reduced in LNCaP cells treated with 10 nM R1881 for 24 and 48 hours as detected by western blot.
Actin was used as a loading control. (C) Repression of PTPRR is also evident in LNCaP cells treated with 0.1 to 100 nM of R1881. Relative PTPRR
expression was detected by real-time PCR. (D) The reduction in PTPRR mRNA expression in response to androgens is still seen in the presence of
1 μg/ml cycloheximide (CHX) as confirmed by real-time PCR. (E) Repression of PTPRR protein expression by the AR is inhibited in the presence of
10 μM of the anti-androgen Casodex (bicalutamide) (lane 6) and by 10 μM of flutamide (F). (G) Depletion of AR protein in LNCaP cells by esiRNA
shows that when the AR is depleted there is no reduction in PTPRR protein in response to androgens. (H) Immunofluorescent staining of LNCaP
cells grown in steroid depleted conditions indicates that PTPRR is localised to the cytoplasm. Bar is 10 μM. The specificity of the antisera was
confirmed with pre-absorption with the immunising peptide, and by detection of over-expressed protein and esiRNA mediated protein depletion
(Additional file 3: Figure S2, Figure 3A and 3D). (I) The PTPRR gene and protein structure is illustrated. The gene consists of 14 exons, and codes for a
74 kDa protein which contains a signal peptide (SD domain), a transmembrane domain (TM) and a kinase interaction motif (KIM).
Munkley et al. BMC Cancer  (2015) 15:9 Page 7 of 11set, the data suggested PTPRR has a heterogeneous
expression profile in prostate tumour clinical samples.
PTPRR expression was detected in half the samples but
either low or undetectable in 3/6 samples (samples 3,4
and 6) despite high expression of four other control
proteins (not shown). PTEN expression was also de-
tected in 5/6 of these clinical PCa samples, but one
tumour (sample 3) had low levels of both PTPRR and
PTEN. Although this sample of tumours is small, these
data suggest individual PCa patients have heteroge-
neous patterns of PTPRR expression relative to other
potential modifier genes (Figure 4C, western blot with
patient information shown below), and might contrib-
ute to the known heterogeneity of prostate tumours.
Discussion
A common feature of aggressive PCa is hyperactivation of
the RAS/ERK1/2 pathway [10,11]. ERK1/2 signalling is
known to play an important role in PCa development [29]
and activation of ERK1/2 has been correlated with malig-
nancy [10-12]. One possible mechanism for RAS/ERK1/2
hyper-activation is loss of function of key negative regula-
tors of the pathway, such as the Sprouty genes. SPRY1 and
SPRY2 function primarily as physiological negative regula-
tors of the RAS/ERK1/2 pathway and act to suppress
prostate tumourigenesis [13,30]. SPRY1 and SPRY2 are
commonly inactivated in PCa where they are linked to
disease progression [22,31,32]. Using network analysis and
a meta-analysis of prior exon array data, we identify con-
comitant down-regulation of a novel androgen-regulated
gene, phosphatase receptor type R (PTPRR) as well as the
known RAS/ERK1/2 pathway negative regulator SPRY1.
Here we show data to suggest that PTPRR is a direct
AR target gene, and is rapidly repressed by androgens in
LNCaP cells. We also demonstrate that over-expression
of PTPRR in androgen stimulated cells is sufficient to
decrease phosphorylation of ERK1/2 and reduce both
the expression of oncogenic transcription factors and
proliferation of prostate cancer cells. The PTPRR geneencodes a classical transmembrane protein-tyrosine phos-
phatase (PTP) receptor type R (PTPRR). PTPRR is nor-
mally expressed in the brain, placenta, small intestine,
stomach, uterus and weakly in the prostate [33]. Mouse
gene Ptprr encodes multiple protein tyrosine phosphatase
receptor type R (PTPRR) isoforms, which display distinct
patterns of expression during neural development [34,35],
and negatively regulate mitogen-activated protein kinase
(MAPK) signalling pathways; both ERK1 and ERK2 are
hyperphosphorylated in the brains of mice deficient for
PTPRR [36]. In cell lines PTPRR has been shown to de-
phosphorylate p44/42 ERK1/2 in response to growth
factors [37,38]. Repression of PTPRR expression via
methylation has been detected in pre-cancerous colorectal
lesions and in cervical adenocarcinoma [39,40], and in
cervical cancer PTPRR may have a role in metastasis and
be a biomarker of invasive cervical cancer [21]. PTPRR ex-
pression has also recently been identified as a prognostic
indicator in oral squamous cell carcinoma [41].
Prostate tumours show huge biological heterogeneity, with
some patients living for 20 years with organ confined
disease, while others progress to lethal metastatic disease
within 2 years of diagnosis. A deeper understanding of this
genomic diversity will help identify genomic changes which
can help distinguish indolent from aggressive PCa. The
RAS/ERK1/2 signalling pathway is mutated in 43% of
primary PCa tumours and 90% of PCa metastases [11]. Al-
though PTPRR is only mutated in 1% of PCa tumours [11],
our data demonstrates that it is a key component of the
clinically important RAS/ERK1/2 signalling pathway, and
that its expression level can have a clear affect on the activity
of this pathway. Recent work has shown that although RAS/
ERK1/2 activation alone cannot initiate PCa development,
RAS/ERK1/2 and PTEN loss cooperate to promote EMT
and metastasis initiated from PCa progenitor cells [12].
Our data also indicate that the importance of PTPRR
expression on the ERK1/2 pathway activity is cell line
and context dependent, suggesting cell background is
important. One potential source of this cell background
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Figure 3 Expression of PTPRR in androgen treated LNCaP cells reduces ERK1/2 signalling and decreases cell proliferation in the
presence of androgens. (A) Over-expression of PTPRR in our LNCaP stable cell lines was confirmed by real-time PCR and by western blotting
(A, left and middle panels). Analysis by western blot revealed that cells over-expressing PTPRR had decreased levels of phospho-ERK1/2 (pERK1/2).
Actin was used as a loading control (A, middle panels). Total levels of ERK2 did not change in these cells (A, right panel). (B) Analysis of three
transcription factors: fra1, c-fos and c-jun, in our stable LNCaP cells by real-time PCR in the presence of androgens revealed decreased expression
levels for all three targets in cells over-expressing PTPRR. fra1, c-fos and c-jun are downstream targets of pERK1/2. (C) Western blotting confirmed
our LNCaP cells to be PTEN negative and our HEK293 cells to be PTEN positive (C, upper left panels). In contrast to what was seen for LNCaP cells,
there is no change in pERK1/2 levels in HEK293 cells over-expressing PTPRR. There was no change in total ERK2 levels. ɑ-tubulin was used as a
loading control (C, lower left and lower right panels). There was also no change in the expression of fra1, c-fos or c-jun expression as detected by
real-time PCR (C, upper right panel). (D) esiRNA mediated depletion of PTPRR in steroid depleted LNCaP cells. Despite loss of PTPRR, there is no
effect on the levels of pERK1/2 (upper panel lanes 3-6) or on the expression of fra1, c-fos or c-jun (lower panel, real-time PCR). (E) LNCaP cells
over-expressing PTPRR and grown in the presence of androgens, had a lower percentage of cells in S phase, as detected by EdU incorporation
(p = 0.039), and also had an impaired rate of proliferation as measured by MTT assay (p < 0.003) (F).
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Figure 4 PTPRR expression in prostate cancer cell lines and in
clinical PCa tissue. (A) Real time PCR analysis of PTPRR expression
in 7 prostate cancer cell lines. The LNCaP cell lines used were:
androgen responsive LNCaP cells grown in the presence (A+) or
absence (SD) of androgens (as described in Figure 1), and in the
presence of 10% FBS (full media, FM), androgen insensitive LNCaP
cells (AI) grown in charcoal stripped FBS, and Casodex resistant
LNCaP cells grown in the presence of 10 μM of the anti-androgen
Casodex. The additional cell lines were: benign prostate hyperplasia
cells (BPH1), androgen independent CWR22RVI, AR-/ PTEN+ DU145
cells, AR+/PTEN- PC3 cells and their metastatic derivative PC3M. All
additional cell lines were grown in 10% FBS. For further details of
the cell lines used see Methods. For real-time PCR samples were
normalised to 3 housekeeping genes (actin, GAPDH and β-tubulin),
and relative to the expression of PTPRR in steroid depleted LNCaP cells.
(B) Expression of PTPRR mRNA in prostate cancer clinical samples as
measured by Ramaswamy et al. [23,24]. The upper panel shows fold
change in 14 prostate cancer tissue samples relative to normal prostate
tissue, and the lower panel shows fold change in 13 metastatic
samples relative to primary prostate cancer tissue, both measured by
Affymetrix Array. (C) Analysis of PTPRR and PTEN protein expression in
6 clinical prostate samples by western blotting. Actin was used as a
loading control. The tumour grade and the patient ethnicity for each
sample are shown in the table.
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in murine PCa progression between loss of PTEN and
SPRY2 [22]. We speculate that similar to SPRY2 the
effects of PTPRR on ERK1/2 signalling might only be
exerted in clinical prostate cancer in the absence of
PTEN (e.g. patient 3 in Figure 4C). Further in vitro and
in vivo studies are required to determine whether loss of
PTPRR is a consistent event in PCa, and whether
reintroduction of PTPRR expression may limit the
progression of CRPCa.Conclusions
In summary, our study has identified the protein tyro-
sine phosphatase PTPRR as an early and direct target of
the androgen receptor that is rapidly repressed by an-
drogens in prostate cancer cells. Further characterisation
of PTPRR protein in LNCaP cells revealed it negatively
regulates the RAS/ERK1/2 pathway and reduces cell
proliferation in response to androgens. Our data suggest
that loss of PTPRR protein might contribute to hyper-
activation of the RAS/ERK1/2 pathway and has important
implications for the development of therapies targeting
this pathway.Additional files
Additional file 1: Figure S2. The specificity of the PTPRR antibody
used was confirmed by peptide blocking with the corresponding
immunising peptide.
Additional file 2: Table S2. Primer sequences used.
Additional file 3: Table S1. IPA Pathway analysis scores.
Munkley et al. BMC Cancer  (2015) 15:9 Page 10 of 11Additional file 4: Figure S1. AR binding sites in ERK1/2 associated
genes. Data for AR ChIP-seq peaks was uploaded from Massie et al. [2]
supplementary data onto UCSC genome browser custom tracks. The
position of AR ChIP-seq peaks detected in LNCaP cells within 100 kb of
the PTPRR gene are illustrated (A). Scale bar is 100 kb. The position of AR
ChIP-seq peaks detected within 100 kb of ADCY1, OPKR1, TRIB1, SPRY1,
PTGER4 and TSPYL2 are shown below (B).
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